Evidence map›Paper›PMID 31940352›Full record

ArticlePloS one2020

Microscopic distance from tumor invasion front to serosa might be a useful predictive factor for peritoneal recurrence after curative resection of T3-gastric cancer.

Shingo Togano, Masakazu Yashiro, Yuichiro Miki, Yurie Yamamoto, Tomohiro Sera, Yukako Kushitani, Atsushi Sugimoto, Shuhei Kushiyama, Sadaaki Nishimura, Kenji Kuroda and 8 more

Erratum issuedOpen access · goldAbstract read
In one paragraph

Article in PloS one, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
1.0field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 11 citations in OpenAlex.

  1. Trial
  2. Article
  3. Article
  4. Article
  5. Observational
  6. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

18 authors at 1 institution in 1 country.

Shingo ToganoDepartment of Gastroenterological Surgery, Osaka City University Graduate School of Medicine, Osaka, Japan.
Masakazu YashiroDepartment of Gastroenterological Surgery, Osaka City University Graduate School of Medicine, Osaka, Japan.ORCID 0000-0001-5743-7228
Yuichiro MikiDepartment of Gastroenterological Surgery, Osaka City University Graduate School of Medicine, Osaka, Japan.
Yurie YamamotoMolecular Oncology and Therapeutics, Osaka City University Graduate School of Medicine, Osaka, Japan.
Tomohiro SeraDepartment of Gastroenterological Surgery, Osaka City University Graduate School of Medicine, Osaka, Japan.
Yukako KushitaniDepartment of Gastroenterological Surgery, Osaka City University Graduate School of Medicine, Osaka, Japan.
Atsushi SugimotoDepartment of Gastroenterological Surgery, Osaka City University Graduate School of Medicine, Osaka, Japan.
Shuhei KushiyamaDepartment of Gastroenterological Surgery, Osaka City University Graduate School of Medicine, Osaka, Japan.
Sadaaki NishimuraDepartment of Gastroenterological Surgery, Osaka City University Graduate School of Medicine, Osaka, Japan.
Kenji KurodaDepartment of Gastroenterological Surgery, Osaka City University Graduate School of Medicine, Osaka, Japan.
Tomohisa OkunoDepartment of Gastroenterological Surgery, Osaka City University Graduate School of Medicine, Osaka, Japan.
Mami YoshiiDepartment of Gastroenterological Surgery, Osaka City University Graduate School of Medicine, Osaka, Japan.
Tatsuro TamuraDepartment of Gastroenterological Surgery, Osaka City University Graduate School of Medicine, Osaka, Japan.
Takahiro ToyokawaDepartment of Gastroenterological Surgery, Osaka City University Graduate School of Medicine, Osaka, Japan.
Hiroaki TanakaDepartment of Gastroenterological Surgery, Osaka City University Graduate School of Medicine, Osaka, Japan.
Kazuya MugurumaDepartment of Gastroenterological Surgery, Osaka City University Graduate School of Medicine, Osaka, Japan.
Sayaka TanakaDepartment of Diagnostic Pathology, Osaka City University Graduate School of Medicine, Osaka, Japan.
Masaichi OhiraDepartment of Gastroenterological Surgery, Osaka City University Graduate School of Medicine, Osaka, Japan.
Osaka City University · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundPeritoneal recurrence is one of the most frequent recurrent diseases in gastric cancer. Although the exposure of cancer cells to the serosal surface is considered a common risk factor for peritoneal recurrence, there are some cases of peritoneal recurrence without infiltration to the serosal surface even after curative surgery. This study sought to clarify the risk factors of peritoneal recurrence in the absence of invasion to the serosal surface. MATERIALS AND

methodsNinety-six patients with gastric cancer who underwent curative surgery were enrolled. In all 96 cases, the depth of tumor invasion was subserosal (T3). The microscopic distance from the tumor invasion front to the serosa (DIFS) was measured using tissue slides by H&E staining and pan-cytokeratin staining. E-cadherin expression was evaluated by immunohistochemical staining.

resultsAmong the 96 patients, 16 developed peritoneal recurrence after curative surgery. The DIFS of the tumors with peritoneal recurrence (156±220 μm) was significantly shorter (p = 0.011) than that without peritoneal recurrence (360±478 μm). Peritoneal recurrence was significantly correlated with DIFS ≤234 μm (p = 0.023), but not with E-cadherin expression. The prognosis of DIFS ≤234 μm was significantly poorer than that of DIFS >234 μm (log rank, p = 0.007). A multivariate analysis of the patients' five-year overall survival revealed that DIFS ≤234 μm and lymph node metastasis were significantly correlated with survival (p = 0.005, p = 0.032, respectively).

conclusionThe measurement of the DIFS might be useful for the prediction of peritoneal recurrence in T3-gastric cancer patients after curative surgery.

Indexed as

AgedCadherinsFemaleGene Expression Regulation, NeoplasticHumansMaleNeoplasm InvasivenessNeoplasm StagingPeritoneal NeoplasmsPrognosisRecurrenceRisk FactorsSerous MembraneStomach NeoplasmsSurvival AnalysisCadherins

Identifiers

PMID31940352
PMCPMC6961828
OpenAlexW3000736098

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.